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Background: Osteonectin (OSN) plays a pivotal role in cardiac remodeling, but predictive
value for OSN in ischemic chronic heart failure (CHF) has not been defined. The aim of the
study was to evaluate the prognostic value of OSN for cumulative survival and hospitali-
zation among patients with ischemic-induced CHF.
Methods: A total of 154 patients with ischemic symptomatic moderate-to-severe CHF were
enrolled in the study at discharge from the hospital. Observation period was up to 3 years
(156 weeks). Blood samples for biomarkers measurements were collected at baseline prior
to study entry. ELISA methods for measurements of circulating level of OSN were used.
Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were
re-admitted. Medians of circulating levels of OSN in survival and died patient cohorts were
670.96 ng/mL (95% confidence interval [CI] ¼ 636.53e705.35 ng/mL) and 907.84 ng/mL (95%
CI ¼ 878.02e937.60 ng/mL). Receiver operation characteristic curve analysis has shown that
cut off point of OSN concentration for cumulative survival function was 845.15 ng/mL. It
has been found a significant divergence of KaplaneMeier survival curves in patients with
high (>845.15 ng/mL) and low (<845.15 ng/mL) concentrations of OSN. Circulating OSN
independently predicted all-cause mortality (odds ratio [OR] ¼ 1.23; 95% CI ¼ 1.10e1.36;
p < 0.001), CHF-related death (OR ¼ 1.46; 95% CI ¼ 1.22e1.80; p < 0.001), and also CHF-related
re-admission (OR ¼ 1.92; 95% CI ¼ 1.77e2.45; p < 0.001) within 3 years of observation period.
Conclusion: Increased circulating secreted protein acidic and rich in cysteine family member
OSN associates with increased 3-year CHF-related death, all-cause mortality, and risk for
recurrent hospitalization due to CHF.rnal Medicine, State Medical University, 26, Mayakovsky Av, Zaporozhye, Ukraine.
Berezin).
g Gung University.
iversity. Publishing services provided by Elsevier B.V. This is an open access article under
mons.org/licenses/by-nc-nd/4.0/).
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Scientific background on the subject
Osteonectin plays a pivotal role in extracellular matrix
remodeling in various diseases, including chronic heart
failure. Elevation of osteonectin associates with cardiac
hypertrophy and impaired heart function. However, the
independent prediction of elevated serumosteonectin in
heart failure patients is still not completely clear.
What this study adds to the field
This study adds new information regarding the predic-
tive role of elevated serum osteonectin in patients with
chronic heart failure. Osteonectin is posed as an in-
flammatory biomarker with possible predictive value.
Results of the study reported being of an independent
association of elevated osteonectin with poor 3-year
prognosis in chronic heart failure patients.Matrix cellular proteins, that is, secreted protein acidic and
rich in cysteine (SPARC), play a key role in postsynthetic pro-
collagen processing in heart failure myocardium and regulate
cell adhesion, growth factor activity, and cell cycle [1]. It has
been found that SPARC family member osteonectin (OSN)
causes myocardial hypertrophy, increased fibrillar collagen
content, stimulates cell signaling, adhesion, survival, prolif-
eration, and migration in several cell types, mediates calcifi-
cation of the vascular wall, coagulation, and endothelial
dysfunction [2]. Moreover, OSN increases collagen deposition
in response to myocardial infarction (MI) or in some types of
cardiac hypertrophy can impair heart function [3]. Recent
animal studies have been revealed that increased circulating
OSN level strongly associates with a higher incidence of
mortality followingMI. Therefore, clinical studies have shown
that serum OSN level relates to increased rates of cardiac wall
rupture and newly, heart failure in MI subjects [4,5]. However,
the role of OSN in ischemic-induced chronic heart failure
(CHF) development and progression has not been defined. The
aim of the study was to evaluate the prognostic value of OSN
for cumulative survival and hospitalization among patients
with ischemic-induced CHF.Methods
The study prospectively evolved 154 patients (86 male, 68 fe-
males) aged 48e62 years with ischemic symptomatic CHF
with IIeIV New York Heart Association (NYHA) class. CHF was
diagnosed according to current European Society of Cardiol-
ogy clinical guidelines [6]. The exclusion criteria are: Q-wave
and non-Q-wave MI within 3 months before study entry; se-
vere kidney and liver diseases that may affect clinical out-
comes;malignancy; creatinine plasma level above 440 mmol/L;
estimated glomerular filtration rate (GFR) < 35 mL/min/m2;
brain injury within 3 months before the enrollment; bodymass index (BMI) above 30 kg/m2; pulmonary edema; tachy-
arrhythmia; valvular heart disease; thyrotoxicosis; ischemic
stroke; intracranial hemorrhage; acute infections; surgery;
trauma; all the ischemic eventswithin three previousmonths;
inflammations within a previous month; neoplasm; preg-
nancy; implanted pacemaker, any disorder that may discon-
tinue patient's participation in the study according to
investigators; and patient's refusal to participate in the study
or to give his consent for it. Observation period was up to 3
years (156 weeks). We analyzed cumulative survival related to
CHF, and additionally all-cause mortality was examined.
Methods for visualization of coronary arteries
Multi-spiral computed contrast enhanced tomography angi-
ography and/or angiographic study have been carried out to
verify the ischemic nature of the disease prior to the study
entry. Angiographic procedure was used when ischemic signs
were presented at baseline, and no MI was found previously.
Multi-spiral computed contrast enhanced tomography angi-
ography was performed when no current ischemic signs/
previously documented old MI at baseline were detected, but
signs and symptoms of CHF were presented. Multi-spiral
computed tomography angiography has been carried out for
all the patients prior to their inclusion in the study. When
atherosclerotic lesions of the coronary arteries were verified,
patients were subjected to the conventional angiographic
examination provided indications for re-vascularization were
available. Coronary artery disease (CAD) was considered to be
diagnosed upon availability of previous angiographic exami-
nations carried out not later than 6 months ago provided no
new cardiovascular events occurred for this period, and the
procedure is available for assay. The coronary artery wall
structure was measured by means of contrast spiral
computed tomography angiography on Somatom Volume
Zoom Scanner (Siemens, Erlangen, Germany) with two de-
tector rows when holding patients breathe at the end of
breathing in [7]. After preliminary native scanning, nonionic
contrast Omnipaque (Amersham Health, Ireland) was
administered for the optimal image of the coronary arteries.
To reconstruct the image, 0.6-mm width axial tomographic
slices were used. When >50% of the diameter of three and
more coronary arteries were found, the multi-vessel disease
was determined.
Transthoracic echocardiography
Transthoracic echocardiography was performed according to
a conventional procedure on ACUSON apparatus, Siemens,
Germany, in В-mode regimen and tissue Doppler echocardi-
ography regimen from parasternal, subcostal, and apical po-
sitions over the short and long axis with phased transducer of
5МHz. Left ventricular end-diastolic and end-systolic volumes
were measured by modified Simpson's method. Left ventric-
ular ejection fraction (LVEF) was assessed in compliance with
the requirements of American Society of Echocardiography
[8]. Tissue Doppler echocardiography was carried out in 4-, 3-
and 2-chamber projections in each of 16 segments of the left
ventricle and in 4 spots of the mitral annulus: At the base of
posterior septal, lateral, inferior, and anterior left ventricular
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diastolic (Аm) myocardial velocities were measured in the
mitral annulus area, followed by calculating velocity of early
diastolic left ventricular filling (E) toАm(Е/Аm) ratio and to Em
(Е/Em) ratio.
Calculation of glomerular filtration rate
GFR was calculated by modification of diet in the renal
disease-6 formula [10].
Measurement of biomarkers
Blood samples were collected at baseline in the morning (at
7e8 am) into cooled silicone test tubes, when patients were
discharged from the hospital with stable clinical status.
Samples were processed according to the recommendations
of the manufacturer of the analytical technique used. They
were centrifuged upon permanent cooling at 6000 rpm for
3 min. Then, plasma samples were stored at a temperature
200 C.
Circulating OSN level was determined by ELISA method
(BenderMedSystems GmbH, Vienna, Austria). N-terminal pro-
brain natriuretic peptide (NT-pro-BNP) concentration was
measured by immunoelectrochemoluminescent assay using
commercial kits produced by Roche (Mannheim, Germany) on
Elecsys 1010 analyzer (Roche, Mannheim, Germany).
Concentrations of total cholesterol (TC) and cholesterol of
high-density lipoproteins were measured by fermentation
method.
Ethical principles
The investigators followed strictly all the requirements to
clinical trials in conformity with the World Medical Associa-
tion declaration of Helsinki, 1964, good clinical practice pro-
vided by International Conference on Harmonization, Council
of Europe Convention for the Protection of Human rights and
dignity of the human being in view of using achievements in
biology and medicine, convention on human rights and
biomedicine, including additional protocol to the convention
on human rights and biomedicine, concerning Biomedical
Research, and legislation of Ukraine. The study was approved
by local IRB (State Medical University, Zaporozhye, Ukraine).
The IRB approval number is 02/21.02.2012. All the patients
have given their written informed consent for participation in
the study.
Statistical analysis
Statistical analysis of the results obtained was carried out in
SPSS system for Windows, Version 20 (SPSS Inc., Chicago, IL,
USA). The datawere presented asmean (М) and standard error
(±SE) or 95% confidence interval (CI); median (Ме); and inter-
quartile range. Design of the study was nonrandomized pro-
spective open cohort study. The sample sizewas computed on
http://www.sealedenvelope.com/power/binary-superiority/.
Our sample size (17 cases in died cohort and 89 cases in sur-
vival cohort) allowed us to detect large effect sizes (>0.80) for
systemic inflammatory marker OSN between survived and
died patients with a power of 80%, taking a two-sided type I
error of 5%. The hypothesis of the normal distribution of theparameters analyzed was checked by means of Kolmogor-
oveSmirnov test. To compare the main parameters of pa-
tients' groups (subject to the type of distribution of the
parameters analyzed), two-tailed Student's t-test or Man-
neWhitney U-test were used. To compare categorical vari-
ables between groups, Chi-square test (c2) and Fisher exact
test were used. The circulating OSN and NT-pro-BNP level in
the blood failed to have a normal distribution, while distri-
bution of the TC and cholesterol fractions had a normal
character (estimated by means of KolmogoroveSmirnov test)
and was not subjected to any mathematical transformation.
Receiver operation characteristic curve (ROC) analysis was
performed to identify the well-balanced cutoff points of the
OSN concentration with the predicted value. To compare
survival rate between two groups Log-rank test was used. The
difference between the areas under ROC curves was calcu-
lated with the method of DeLong et al. and reclassification
measures (index discrimination improvement [IDI]) [11,12].
Odds ratio (OR) and 95% CI were calculated for all the inde-
pendent predictors of survival of the patients. A calculated
difference of p < 0.05 was considered significant.Results
General characteristics of study patient population
During a median follow-up of 2.18 years, 21 participants died,
and CHF-related death was defined in 18 patients. Addition-
ally, 106 subjects were hospitalized repetitively due to
advance CHF (17 cases in died cohort and 89 cases in survival
cohort). Table 1 shows a general characteristic of the patients
included in the study. As one can see from Table 1, no sub-
stantial age and gender differences were found among per-
sonswho died and survived, aswell as differences in BMI, GFR,
glycated hemoglobin, fasting blood glucose level, blood
creatinine level, TC, low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol, and numerous of coro-
nary vessels were damaged. No differencewas found between
the two cohorts in systemic office blood pressure and heart
rate. Documented incidence of type 2 diabetes mellitus
(T2DM) in patients of the two cohorts was 38.1% and 33.8%
(p ¼ 0.06). Note that there was not a statistically significant
change in Е/Аm and Е/Em between the two cohorts, while a
decrease in the LVEF value was quite anticipated in the setting
in dead patients. At the same time, the level of circulating NT-
pro-BNP was statistically significantly higher in dead patients
than in survived persons. When analyzing details of phar-
macotherapy, no substantial differences were found between
the two cohorts with regard to the administration of the ma-
jority of drugs.Circulating osteonectin level in survived and dead patients
Medians of circulating levels of OSN in survived and dead
patient cohort were 670.96 ng/mL (95% CI ¼ 636.53e705.35 ng/
mL) and 907.84 ng/mL (95% CI ¼ 878.02e937.60 ng/mL)
(p < 0.001).
Table 1 e General characteristic of patients participating in the study.
Variables All patients (n ¼ 154)
(%)
Subjects who were died
(n ¼ 21) (%)
Subjects who were survived
(n ¼ 133) (%)
Age, years (mean ± SD) 58.50 ± 6.10 57.20 ± 6.70 59.50 ± 7.30
Males, n (%) 79 (51.3) 12 (57.1) 67 (50.3)
Hypertension, n (%) 73 (47.4) 12 (57.1) 61 (45.9)
Hyperlipidemia, n (%) 61 (39.6) 9 (42.8) 52 (39.1)
T2DM, n (%) 53 (34.4) 8 (38.1) 45 (33.8)
Adherence to smoking, n (%) 31 (20.1) 7 (33.3) 24 (29.3)
II class NYHA, n (%) 41 (26.6) 6 (28.6) 35 (26.3)
III class NYHA, n (%) 74 (48.1) 9 (42.8) 65 (48.9)
IV class NYHA, n (%) 39 (25.3) 6 (28.6) 33 (24.8)
BMI, kg/m2 (mean, 95% CI) 23.9 (22.8e26.1) 23.7 (22.5e27.3) 24.2 (22.0e27.9)
GFR, mL/min/1.73 m2 (mean, 95% CI) 83.4 (70.2e91.3) 82.1 (69.9e93.1) 85.2 (70.3e112.5)
HbA1c (%) 6.5 (4.7e8.6) 6.3 (4.4e9.0) 7.0 (4.3e9.2)
Fasting blood glucose, mmol/L (mean, 95% CI) 4.95 (3.8e8.0) 4.80 (3.6e8.5) 5.40 (3.4e9.1)
Creatinine, mmol/L (mean, 95% CI) 72.6 (61.3e82.5) 70.5 (59.6e88.3) 74.9 (65.1e90.3)
TC, mmol/L (mean, 95% CI) 5.1 (4.7e5.6) 5.3 (4.6e6.0) 5.0 (4.2e5.8)
LDL-C, mmol/L (mean, 95% CI) 3.35 (3.16e4.02) 3.60 (3.20e4.18) 3.02 (2.80e3.90)
HDL-C, mmol/L (mean, 95% CI) 0.92 (0.90e1.02) 0.94 (0.92e1.06) 0.88 (0.82e0.97)
NT-pro-BNP, pg/mL (mean, 95% CI) 1266.1 (811.5e2220.7) 1533.6 (644.5e2560.6) 1031.2 (704.8e1560.7)*
Osteonectin, ng/mL (mean, 95% CI) 788.54 (665.12e912.30) 907.84 (878.02e937.60) 670.96 (636.53e705.35)*
Systolic BP, mm Hg (mean, 95% CI) 131 (127e135) 129 (126e133) 135 (130e139)
Diastolic BP, mm Hg (mean, 95% CI) 77 (73e82) 77 (72e82) 78 (73e82)
HR, beats per 1 min (mean, 95% CI) 71 (68e75) 76 (72e79) 68 (63e74)
LVEF, % (mean, 95% CI) 47.60 (42.5e54.3) 42.80 (40.1e44.6) 52.40 (46.1e55.4)*
Е/Аm, U (mean, 95% CI) 16.6 (15.9e17.2) 16.6 (16.0e17.3) 16.5 (15.6e17.9)
Е/Em, U (mean, 95% CI) 16.6 (15.8e17.5) 16.6 (15.7e17.5) 16.6 (15.5e17.8)
One coronary artery lesion, n (%) 29 (18.8) 5 (23.8) 24 (18.0)
Two coronary arteries lesion, n (%) 64 (41.6) 8 (38.1) 54 (40.6)
Three-and multi-vessel lesion of coronary
arteries, n (%)
63 (40.9) 8 (38.1) 55 (41.4)
ACEI/ARAs, n (%) 154 (100) 21 (100) 133 (100)
Acetylsalicylic acid, n (%) 130 (84.4) 19 (90.5) 121 (91.0)
Other antiplatelets, n (%) 14 (9.1) 2 (9.5) 12 (9.0)
Statins, n (%) 94 (61.0) 14 (66.7) 80 (60.2)
Metformin, n (%) 53 (34.4) 8 (38.1) 45 (33.8)
Diuretics, n (%) 139 (90.3) 18 (85.7) 121 (91.0)
Mineralocorticoid receptor antagonist, n (%) 79 (51.3) 9 (42.9) 70 (52.6)
Data are presented as mean and 95% CI; categorical variables are expressed as numerous (n) and percentages (%). P value is a comparison of
mean ormedian variables between both cohorts. *Statistically differences between parameters (P < 0.05). Abbreviations: CI: Confidence interval;
CAD: Coronary artery disease, T2DM: type 2 diabetes mellitus; GFR: glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; LDL-
C: low-density lipoprotein cholesterol; BMI: body mass index; LVEF: left ventricular ejection fraction; U: unit; Em: early diastolic myocardial
velocity; Аm: late diastolic myocardial velocity; E: peak velocity of early diastolic left ventricular filling; ACEI: angiotensin-converting enzyme
inhibitor; ARAs: angiotensin-2 receptors antagonists; SD: standard deviation; NYHA: New York Heart Association; HbA1c: glycated hemoglobin;
BP: blood pressure; TC: total cholesterol; NT-pro-BNP: N-terminal pro-brain natriuretic peptide; HR: heart rate.
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patient population
Multivariate logistic regression was used to assess whether
any combination of assays was able to better discriminate
between survived and dead patients. In the logistic regression
analysis, the main factors independently related with cumu-
lative mortality and CHF-related readmission were some
biomarkers (OSN alone, NT-pro-BNP alone), LVEF, T2DM, and
three- andmulti-vessel lesion. Circulating OSN independently
predicted all-cause mortality (OR ¼ 1.23; 95% CI ¼ 1.10e1.36;
p < 0.001), CHF-related death (OR ¼ 1.46; 95% CI ¼ 1.22e1.80;
p < 0.001), and also CHF-related readmission (OR ¼ 1.92; 95%
CI ¼ 1.77e2.45; p < 0.001) within 3 years of observation period
[Table 2]. NT-pro-BNP and LVEF remained statistically signif-
icant for all categories: All-causemortality, CHF-related death,and CHF-related readmission, whereas T2DM and three- and
multi-vessel lesion for all variables were not.
Using a stepwisemodel selectionmethod formulti-variable
prediction model we have been investigated the summary ef-
fect of any combinations of OSN, NT-pro-BNP, LVEF on all-
cause mortality, CHF-related death, and CHF-related read-
missions.We found that OSNalone (Model 1) and combination
of OSN with NT-pro-BNP (Model 2) remained statistically sig-
nificant predictors for all-causemortality (B-coefficient¼ 1.14,
p¼ 0.001 and B-coefficient¼ 1,14, p¼ 0.001, respectively), CHF-
related death (B-coefficient ¼ 2.24, p ¼ 0.003 and B-
coefficient ¼ 2,76, p ¼ 0.008, respectively), and CHF-related
recurrent hospitalizations (B-coefficient ¼ 2.06, p ¼ 0.003 and
B-coefficient ¼ 2,11, p ¼ 0.004, respectively), whereas combi-
nationofOSNwithbothNT-pro-BNPandLVEF (Model4)didnot
(B-coefficient ¼ 0.014, p ¼ 0.543 and B-coefficient ¼ 0.016,
Table 2 e Independent variables related to 3-years all-cause mortality, CHF-related death, and CHF-related readmission.
Variables All-cause mortality CHF-related death CHF-related
readmission
OR 95% CI p OR 95% CI p OR 95% CI p
OSN (<845.15 ng/mL vs. >845.15 ng/mL) 1.23 1.10e1.36 0.006 1.46 1.22e1.80 0.004 1.92 1.77e2.45 0.001
NT-pro-BNP (>1250.4 pg/mL vs. <1250.4 pg/mL) 1.09 1.02e1.16 0.002 1.42 1.22e1.73 0.006 1.44 1.28e1.67 0.002
LVEF (<45% vs. >45%) 1.06 1.01e1.12 0.001 1.15 1.12e1.18 0.014 1.22 1.07e1.45 0.016
T2DM (present vs. absent) 1.05 1.01e1.11 0.001 1.03 0.93e1.10 0.32 1.04 0.97e1.06 0.42
Three-and multi-vessel lesion of coronary
arteries (present vs. absent)
1.02 0.88e1.09 0.56 1.01 0.92e1.07 0.27 1.14 1.03e1.26 0.012
Abbreviations: OR: odds ratio; CI: confidence interval; LVEF: left ventricular ejection fraction; BNP: brain natriuretic peptide; T2DM: type 2
diabetes mellitus; CHF: chronic heart failure; OSN: osteonectin; NT-pro-BNP: N-terminal pro-brain natriuretic peptide.
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pro-BNP alone (Model 3) predicted CHF-related recurrent ad-
missions (B-coefficient ¼ 1.88, p ¼ 0.001) only, whereas all-
cause mortality (B-coefficient ¼ 0.025, p ¼ 0.68) and CHF-
related death (B-coefficient ¼ 0.036, p ¼ 0.62) did not. In fact, a
stepwise model selection method demonstrated that LVEF,
T2DM and three- and multi-vessel lesion of coronary arteries
added to combination of OSN andNT-pro-BNPdo not offer any
additional information to discriminate between survived and
dead patients with CHF (B-coefficient of 0.012, 0.067, and 0.023,
respectively; P values of 0.277, 0.300, and 0.522, respectively).
The optimum cut-off point for OSN is determined by the
relative importance of the sensitivity and specificity of the test.
ROC curve analysis has shown that cut-off point of OSN con-
centration for cumulative cardiovascular events was
845.15 ng/mL [Fig. 1]. Area under curve was 0.918 (SE ¼ 0.022;
95% CI ¼ 0.876e0.961), sensitivity and specificity were 79.2%
and 84.4%, respectively. Derived from ROC curve, a NT-pro-
BNP cut-off of 1250.4 pg/mL showed the best-balanced sensi-
tivity and specificity for predicting mortality and hospital
readmission (72.3% sensitivity and 81.6% specificity). Using
cut-off points for OSN and NT-pro-BNP over mentioned above
we found that the discriminative ability for both biomarkers
showed a small trend to increase only. Combination of both
biomarkers leads increased sensitivity up 88.6%and specificity
up 92.4%. Model discrimination was excellent for OSN alone,
NT-pro-BNP alone, and both in combination. For determina-
tion of thedifference between theROCcurves,weusedDeLong
method and reclassification measures (IDI). Using DeLong
method we found a statistical difference between areas under
curves that are suitable for OSN alone, NT-pro-BNP alone and
its combination were found (p < 0.001 for all cases). Integrated
discrimination improvement after the inclusion of NT-pro-
BNP into the model was calculated. However, we found that
the inclusion of NT-pro-BNP does not significantly improved
model discrimination based on OSN alone (AUC 0.961 vs. AUC
0.918, p ¼ 0.22; and IDI ¼ 0.035, p ¼ 0.42). The difference be-
tween discrimination for OSN alone and NT-pro-BNP alone
was not significant to the IDI (IDI ¼ 0.031; p ¼ 0.38) [Table 3].
It has been found a significantly divergence of
KaplaneMeier survival curves in patients with high
(>845.15 ng/mL) and low (<845.15 ng/mL) concentrations of
OSN [Fig. 2]. The curves divergence of events accumulation
reached a statistical significance in 26 weeks of the observa-
tion period (p < 0.001).Discussion
The results of the study clarify being of positive association
between circulating level of SPARC family member OSN and
increased 3-year combined cardiovascular events (CHF-
related death, all-cause mortality, and readmission due to
CHF) among patient population with ischemic-induced
symptomatic cardiac failure. Recently, OSN was not defined
as a biological marker with possible predictive value in heart
failure subjects, although its role as a surrogate biomarker of
the atherosclerotic lesion and cardiovascular remodeling was
well-established.
It is well-known that extracellular matrix (ECM) proteins
maymodulate cell-matrix interactions and cell functions, and
does not seem to have a direct structural role and mediates
left ventricular remodeling. Several members of the matrix
cellular protein family, like OSN, are up-regulated in CHF. OSN
(also known as SPARC) is synthesized by wide spectrum cells,
such as osteoblasts, fibroblasts, and activatedmacrophages at
sites of wound repair and platelet degranulation [3]. It is found
in the serum of patients with CHF predominantly reflected a
positive pro-inflammatory response and alterations in protein
metabolism that leads to biomechanical stress [2e4]. OSN also
regulates the proliferation of some cells, especially endothe-
lial cells, mediated by its ability to bind to cytokines and
growth factor [5]. Excess degradation and disruption of the
cardiac ECM network structure thereby, OSN overexpression
is the formation of fibrotic lesions. Because myocardial
fibrosis is also a well-known cause of diastolic dysfunction
and CHF, remodeling of ECM is considered as a key aspect of
the myocardial response to biomechanical stress and
advanced heart failure [13].
Recent studies have been suggested that SPARC, such as
OSN, osteopontin, and osteoprotegerin, presumably can play
an important role in not only CHF, but in atherogenesis also
[14,15]. The animal models give evidence that OSN levels
directly correlate with increased mortality post-MI due to
increased rupture rate [16]. Probably, this effectmay be related
to OSN inhibition ability of mitogenesis of the vascular
endothelial growth factor on microvascular endothelial cells
[17]. Because OSN may induce deadhesion, through loss of
actin fibers and focal adhesion plaques, cell migration and cell
infiltration of the vulnerable zone of plaque may facilitate.
Therefore, OSN may regulate MMP activity involving matrix
Fig. 1 e Results of the receiver operation characteristic analysis: The graphical plot illustrates the predictive discriminations for
osteonectin alone, NT-pro-BNP alone, and Osteonectin with N-terminal pro-brain natriuretic peptide for chronic heart failure
patients.
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Both these processes are considered a pivotal mechanism for
triggering plaque instability as well as heart wall rupture [19].
Thus, OSN is multi-functional matrix protein with powerful
ability to inhibition of tissue response to injury and probably,
to the mediation of low-intensity inflammation. As a fact, the
predictive role of OSN in cardiovascular diseases is uncertain.
Taken together the data mentioned above, clarify that OSN
may be considered as a biological marker with high predictiveTable 3 e C-statistic calculated for predictive models
based on biomarker measurement.
Model AUC IDI p
Model 1 (OSN alone) 0.918 e e
Model 2 (NT-pro-BNP alone)
versus Model 1
0.865 0.031 0.38
Model 3 (OSN þ NT-pro-BNP)
versus Model 1
0.961 0.035 0.42
Abbreviations: IDI: index discrimination improvement; CI: confi-
dence interval; AUC: area under curve; OSN: osteonectin; NT-pro-
BNP: N-terminal pro-brain natriuretic peptide.value for CHF evolution, especially for patients with ischemic
causes of myocardial dysfunction.
Currently, there are no data on the utility or discriminatory
ability of OSN in determining the mortality from CHF. It is
predisposed that increased OSN concentration would be a
powerful indicator of not only CHF-related events, but also all-
cause mortality. We found that circulating OSN level was
really increased in CHF patients with poor short-term prog-
nosis. Indeed, OSN concentration independently predicted
combined cardiovascular events. On the one hand, OSN is
secreted by activated macrophages due to pro-inflammatory
activation and leads profound ECM reposition, exaggerated
left ventricular remodeling, endothelial dysfunction, vascular
calcification, and procoagulation [1,3]. On the other hand,
given results of recent investigations, the absence of tissue
over-expression of OSN is associated with increased cardiac
rupture and dysfunction after acute MI due to worsening
postsynthetic procollagen processing [4,20]. There are pre-
dispositions that these mechanisms, which are involved in
reparation processes of heart and vessels, are under the con-
trol ofmineralocorticoid receptors. It has been postulated that
beneficial effects of mineralocorticoid receptor antagonist
eplerenone in CHF were associated with normalization of
Fig. 2 e The KaplaneMeier survival plot shows the
significant difference in cumulative survival between patient
groups with low (<845.15 ng/mL) and high (>845.15 ng/mL)
circulating osteonectin.
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Decreased expression of OSN improves cardiac structural and
functional parameters, delaying the progression of heart
failure that was found in the small animal study [21]. Thus,
the role of OSN in cardiac outcomes is probably controversial.
Probably, treatment strategymight particularly explain the
interrelation of OSN with outcomes in the patient population.
We enrolled in our study, patients with ischemic-induced CHF
treated with eplerenone also. At least 42.9% and 52.6% pa-
tients of the both cohorts (dead persons and survived subjects)
are given high selectivemineralocorticoid receptor antagonist
eplerenone. Despite similar co-administration of eplerenone
with standard heart failure therapy, no significant effect of
medication for a survival rate of the patients with CHF was
found. Probably, collagen deposition as functions in the
extracellular processing that is controlled by OSN is a key
protective event for acute MI, whereas for advance CHF
similar process is considered the potential harm and prog-
nostically negative [2,3,5]. Obviously, structural changes of the
ECM are significantly modulated by OSN associated several
signaling pathways, which are differed on their ability to
induce repair changes on the several stages on cardiovascular
continuum [22,23]. It may have important value for reclassi-
fication of the patients at high risk of cardiovascular outcomes
related to several causes, which are suitable for ischemic CHF.
A variety of biomarkers have been investigated on their values
to predict cardiovascular outcomes, but OSN was not [24]. We
determined that predictive value of circulating OSN was su-
perior when compared with NT-pro-BNP alone. Taken into
consideration that a significant divergence of KaplaneMeier
survival curves in patients with high (>845.15 ng/mL) and low(<845.15 ng/mL) concentrations of OSN within 26 weeks was
found. The convergence of KaplaneMeier survival curves at
the end of the study was not found. There are preexisted data
about age-related increasing of OSN, but we found no sub-
stantial age and gender differences of OSN among persons
who were experienced combined cardiovascular events and
who were not [15]. Because the weak association between
echocardiographic features and NYHA class was previously
determined, we added circulating OSN level to conventional
prognostic model, which included NT-pro-BNP and LVEF. In
fact, large prospective studies are required to provide robust
evidence of the prognostic role of combination OSN and NT-
pro-BNP on the mortality rate among CHF persons.
In fact, long-term prospective studies are required to pro-
vide robust evidence of the prognostic role of combination
OSN and NT-pro-BNP in the associated mortality from CHF.
However, some limitation of our study, such as small size,
absence of randomization, and probably, conventional treat-
ment of CHF without biological markers-guided control, may
limit real-time prognostic value of OSN leading increased
statistical power. In this study, OSN level was measured at
baseline after discharge of the patients from the hospital with
stable CAD and without clinical signs and symptoms of acute
decompensated CHF. It can introduce some limitations to the
interpretation of the results of the investigation, especially
around OSN level in CHF subjects independently before
readmission. Needed new studies are required for determi-
nation whether OSN may predict cardiovascular outcomes in
ischemic CHF patients. Therefore, understanding the mech-
anisms that contribute to the cardiac remodeling may help to
design new studies aimed at determination of OSN role
in CHF.
Conclusion
We found that increased circulating SPARC family member
OSN closely associates with increased 3-year combined car-
diovascular events (CHF-related death, all-cause mortality,
and recurrent hospitalization due to CHF). Using a combina-
tion of OSN and NT-pro-BNP showed the best-balanced
sensitivity and specificity for predicting mortality and hospi-
tal readmission in ischemic CHF subjects.Limitations of the study
This study has some limitations. We believed that a greater
cohort would be desirable to improve the power of the study.
Therefore, serial measurements of OSN will be desirable for
determination of the biomarker level in patients at read-
mission and after discharge from the hospital. Dynamic of
OSNmay have powerful value for prediction of cardiovascular
outcomes and it is able to be considered a part of guided
therapy of CHF in perspective. We also relied on clinical data
to rule out infection and other inflammatory diseases before
sampling, but we could not exclude that some patients had
unrecognized the conditions responsible for the elevated OSN
levels observed. We supposed to mean that these limitations
would not have a significant influence to study data
interpretation.
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